Vaccine Effectiveness of 3 Versus 2 Doses of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA Vaccines in a High-Risk National Population

BACKGROUND: Knowledge of the vaccine effectiveness (VE) of a third or booster vaccine dose in preventing SARS-CoV-2 infection or its consequences is critical in developing recommendations for their use. We determined relative VE of 3 vs 2 doses of an mRNA vaccine in preventing symptomatic SARS-CoV-2...

Descripción completa

Detalles Bibliográficos
Autores principales: Butt, Adeel A, Talisa, Victor B, Yan, Peng, Shaikh, Obaid S, Omer, Saad B, Mayr, Florian B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8903438/
https://www.ncbi.nlm.nih.gov/pubmed/35245940
http://dx.doi.org/10.1093/cid/ciac178

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8903438/
https://www.ncbi.nlm.nih.gov/pubmed/35245940
http://dx.doi.org/10.1093/cid/ciac178

Ejemplares similares